COMMON STOCK PURCHASE WARRANT To Purchase [ ] Shares of Common Stock of SCOLR Pharma, Inc.Common Stock Purchase Warrant • March 24th, 2010 • SCOLR Pharma, Inc. • In vitro & in vivo diagnostic substances
THIS COMMON STOCK PURCHASE WARRANT CERTIFIES that, for value received, (the “Holder”), is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date that is six (6) months from the date hereof, but not before, and on or before the close of business on the Termination Date (as defined below) but not thereafter, to subscribe for and purchase from SCOLR Pharma, Inc. a corporation incorporated in the State of Delaware (the “Company”), up to [ ] shares (the “Warrant Shares”) of Common Stock, of the Company (the “Common Stock”). The purchase price of each full share of Common Stock (the “Exercise Price”) under this Warrant shall be SEVENTY FIVE CENTS ($0.75), subject to adjustment hereunder. The Exercise Price and the number of Warrant Shares for which the Warrant is exercisable shall be subject to adjustment as provided herein. As used herein “Termination Date” shall mean March 12, 2015. Capitalized terms us
SCOLR PHARMA, INC. UNIT PURCHASE AGREEMENTUnit Purchase Agreement • March 24th, 2010 • SCOLR Pharma, Inc. • In vitro & in vivo diagnostic substances • New York
This UNIT PURCHASE AGREEMENT (as amended or supplemented from time to time, this “Agreement”) is made as of this 12th day of March, 2010, between SCOLR PHARMA, INC., a Delaware corporation with its principal offices at 19204 North Creek Parkway, Suite 100, Bothell, Washington 98011 (the “Company”), and the undersigned (the “Subscriber”).
AMENDMENT NUMBER 3 TO MANUFACTURE, LICENSE AND DISTRIBUTION AGREEMENTManufacture, License and Distribution Agreement • March 24th, 2010 • SCOLR Pharma, Inc. • In vitro & in vivo diagnostic substances
This Amendment Number 3 to the Manufacture, License and Distribution Agreement by and between Perrigo Company of South Carolina, Inc. (“Perrigo”), and SCOLR Pharma, Inc. (“SCOLR”) dated October 20, 2005, as amended by Amendment Number 1 dated November 14, 2008 and Amendment Number 2 dated April 24, 2009 (the “Agreement”) is dated as of January 4, 2010 and effective as of January 1, 2010 (the “Amendment Effective Date”).
LICENSE AGREEMENTLicense Agreement • March 24th, 2010 • SCOLR Pharma, Inc. • In vitro & in vivo diagnostic substances • Washington
In consideration of the promises contained in this Agreement and of other consideration (the receipt and sufficiency of which is acknowledged by the parties hereto), the parties agree as follows:
Term Sheet: SCOLR’s Ondansetron ER Licensing Agreement February 2010 The purpose of this licensing term sheet (“Term Sheet”) is to set forth the terms for an exclusive worldwide license agreement between SCOLR Pharma Inc., a Delaware corporation, or...Licensing Agreement • March 24th, 2010 • SCOLR Pharma, Inc. • In vitro & in vivo diagnostic substances
